Dr Amir Zalcenstein

Investment Manager

PhD, MBA

 


ONEV-2568-BIOPROFILE.jpg


Biography

Amir Zalcenstein has relocated to Melbourne from Israel in 2014.  Prior to joining OneVentures and while in Israel, Amir was Head of Business Development for BiondVax, a publicly traded company developing a Universal Flu Vaccine. Prior, Amir served as CEO of Amorphical (developing the next generation of Calcium-based therapies) and SoluBest, a drug delivery company advancing a proprietary technology for oral delivery of insoluble drugs. 

Amir holds a PhD in Molecular Biology from the Weizmann Institute of Science and an Executive MBA from Technion, Israel. 

Amir brings a strong Israeli venture perspective to the team and extensive international operational experience.

Location

Melbourne

Founded

Targia Pharmaceuticals